Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® in Stage III Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
01 nov. 2021 08h00 HE
|
Provectus Biopharmaceuticals Inc.
184 patients: 44.9 months median overall survival774 PV-10-injected lesions (121 patients): 56% complete response KNOXVILLE, TN, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress
27 sept. 2021 06h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
24 avr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
19 avr. 2018 06h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...